Skip to content
OpenCapital
Get started

BioLife Solutions BLFS Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Azenta logo
AzentaAZTA
——

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02—

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%—
Operating margin-16.7%—
Net margin-68.7%—
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0×0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
BioLife Solutions (BLFS) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $151K in Q1 2026.
How has BioLife Solutions's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
BioLife Solutions's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 1577.8% year-over-year, from $9K to $151K.
What is the long-term trend for BioLife Solutions's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Over 3 years (2022 to 2025), BioLife Solutions's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -56.3% compound annual growth rate (CAGR), from $60K to $5K.